Methods: Virus isolates were tested for adamantane susceptibility, using pyrosequencing to detect the S31N marker of adamantane resistance in the M2 protein and biological assays to assess viral replication in cell culture. To assess neuraminidase (NA) inhibitor (NAI) susceptibility, virus isolates were tested in chemiluminescent NA inhibition assays and by pyrosequencing to detect the H275Y (H274Y in N2 numbering) marker of oseltamivir resistance in the NA. Results: With the exception of three, all viruses that were tested for adamantane susceptibility (n=3,362) were resistant to this class of drugs. All viruses tested for NAI susceptibility (n=3,359) were sensitive to two US Food and Drug Administration-approved NAIs, oseltamivir (mean ±sd 50% inhibitory concentration [IC 50 ] 0.25 ±0.12 nM) and zanamivir (mean IC 50 0.29 ±0.09 nM), except 23 (0.7%), which were resistant to oseltamivir, but sensitive to zanamivir. Oseltamivir-resistant viruses had the H275Y mutation in their NA and were detected in patients exposed to the drug through prophylaxis or treatment. NA activity of all viruses was inhibited by the NAIs peramivir, laninamivir (R-125489) and A-315675, except for H275Y variants, which exhibited approximately 100-fold reduction in peramivir susceptibility. Conclusions: This report provides data regarding antiviral susceptibility of 2009 pandemic influenza A (H1N1) surveillance viruses, the majority of which were resistant to adamantanes and sensitive to NAIs. These findings provide information essential for antiviral resistance monitoring and development of novel diagnostic tests for detecting influenza antiviral resistance.
The recent emergence and rapid global spread of the 2009 pandemic influenza A (H1N1) viruses among humans [1] [2] [3] raised public health concerns and prompted the World Health Organization (WHO) to officially declare a pandemic in early June 2009. In addition to vaccines currently available for protection against the 2009 pandemic influenza A (H1N1) viruses [4] , antiviral drugs remain a key component of the public health response and are expected to play an essential role in the reduction of morbidity and mortality caused by infection with the pandemic viruses, especially for treatment and chemoprophylaxis of populations at high risk of influenza-associated complications.
The pandemic influenza A (H1N1) viruses possess a combination of genes that have not been previously reported in swine or human influenza viruses in the US or elsewhere [3] . Six of their eight gene segments are related to those of triple reassortant swine influenza viruses found among pigs in the US, whereas the two remaining gene segments essential for drug susceptibility (neuraminidase [NA] and M) are of Eurasian swine genetic lineage [3, 5] . Their M2 protein contains the S31N amino acid change associated with resistance to adamantanes (amantadine and rimantadine) [3, 6] . The initial reports based on neuraminidase inhibition (NI) assays indicated that the 2009 pandemic viruses were sensitive to the neuraminidase inhibitors (NAIs) oseltamivir and zanamivir [2, 6, 7] , and no genetic markers known to be linked to decreased NAI sensitivities were found in their NA [3] . The goal of this study was to
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Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro
Introduction provide a comprehensive analysis of the susceptibility of the pandemic viruses to antiviral drugs that have been approved by the US Food and Drug Administration (FDA), as well as to NAIs currently in development. This information will assist in guiding the use of antiviral agents for treatment and prophylaxis of the pandemic influenza, and will also provide essential information for antiviral resistance monitoring and diagnosis. Tables 1 and 2 .
Methods
Viruses
Cell cultures
MDCK cells were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum, 50 units/ml penicillin and 50 µg/ml streptomycin (Invitrogen, Carlsbad, CA, USA).
Assessing virus susceptibility to adamantanes
Pyrosequencing assays for detection of established markers of adamantane resistance in the M2 protein Viral RNA extraction, reverse transcription PCR (RT-PCR) and pyrosequencing to detect established molecular markers of adamantane resistance in the M2 protein were performed as previously described for 2009 pandemic H1N1 viruses [8] . Following fixation, the 70% ethanol was discarded and replaced with 1 ml of Gram crystal violet stain (BD Biosciences, Franklin Lakes, NJ, USA) for 5-10 min at room temperature. The crystal violet stain was then discarded and cells were washed twice with PBS (pH 7.2). Plaques were visualized and photographed, and the numbers of plaques in each well were counted. The concentrations of drug that reduced the number of plaques by 50% compared with a control (EC 50 ) were calculated using GraphPad Prism version 5.00 (GraphPad Software, Inc., La Jolla, CA, USA). The criterion for virus sensitivity to amantadine and rimantadine was EC 50 <1 µg/ml. Viruses with EC 50 values ≥1 µg/ml were considered as resistant to adamantanes.
Plaque inhibition assays
Virus yield reduction assays
Confluent MDCK cell monolayers in 96-well plates were washed with PBS and pretreated with 50 µl of DMEM supplemented with 0.2% bovine serum albumin (BSA) containing either amantadine or rimantadine at concentrations ranging from 0.39 to 100 µg/ml. Plates were incubated with drugs for 30 min at 37°C followed by inoculation of 25 µl of virus at a multiplicity of infection of 30-60 per well. Inoculated plates were incubated for 1 h at 4°C to allow virus adsorption, after which the inoculum was removed and cells were washed once with PBS. Thereafter, 100 µl of DMEM (with 0.2% BSA and 2 µg/ml TPCK-treated trypsin) and the corresponding concentration of drug were added into each well. The treated cultures were then incubated at 37°C for 24 h, at which point supernatants were removed and stored at -70°C. Virus yields in the supernatants were determined using the focus formation assay as described below. Each drug dilution was tested in quadruplicate and virus yield was expressed as log 10 focus-forming units (FFU)/well. The criterion for sensitivity to amantadine and rimantadine was a reduction of virus yield by ≥1 log 10 infectious particles/100 µl at a drug concentration of <1 µg/ml.
Determination of infectious virus yield in focus formation assays
Confluent MDCK cell monolayers in 96-well plates were washed with PBS and then infected with 10-fold serial virus dilutions and incubated for 1 h at 4°C. The unadsorbed virus was removed and cells were washed once with PBS and then overlaid with fresh DMEM supplemented with 0.2% BSA and 2 µg/ml TPCK-treated trypsin. Plates were incubated at 37°C for 24 h, after which the supernatants were discarded and cells fixed with ice cold methanol/acetic acid (v/v 95/5). Fixed cell monolayers were immunostained with an anti-influenza A nucleoprotein (NP) murine monoclonal antibody blend (MAB8251; Millipore, Temecula, CA, USA) followed by 1 h incubation with horse radish peroxidase-conjugated secondary antibody (Millipore, Billerica, MA, USA). After addition of the precipitate-forming True Blue peroxidase substrate (KPL Inc., Gaithersburg, MD, USA), plates were incubated for another 30 min. Stained clusters of infected cell (foci)-expressing NP viral antigen were counted using an Axiovert 40 inverted microscrope (Carl Zeiss, Göttingen, Germany) and virus yield was expressed as log 10 FFU/100 µl. An individual FFU is formed by a cluster of at least five neighbouring stained cells.
Assessment of virus susceptibility to neuraminidase inhibitors
Chemiluminescent neuraminidase inhibition assays Susceptibilities of virus isolates to oseltamivir carboxylate (Hoffman-La Roche) and zanamivir (GlaxoSmithKline, Uxbridge, UK) were assessed as previously described [9] in the chemiluminescent NI assay using the NA-Star™ Kit (Applied Biosystems, Foster City, CA, USA), which utilizes a 1,2-dioxetane derivative of sialic acid as substrate [10] . Additionally, subsets of virus isolates were tested for susceptibility to peramivir (BioCryst Pharmaceuticals, Birmingham, AL, USA), laninamivir (R-125489) (Biota, Melbourne, Australia) and A-315675 (Abbott Laboratories, Abbott Park, IL, USA).
Statistical analyses
Calculation of the drug concentration required to inhibit 50% of NA enzyme activity (IC 50 ) and curve-fitting were performed using Robosage version 7.31 software, an add-in for Microsoft Excel (Microsoft Corp., Redmond, WA, USA) using the equation y=V max ×{1-[x/ (K+x)]}, where V max is the maximum rate of metabolism, x is the inhibitor concentration, y is the response being inhibited and K is the IC 50 for the inhibition curve (that is, y=50% V max when x=K) [9] . Box and whisker plot analyses of log-transformed IC 50 Neuraminidase sequence analysis to detect markers of resistance to oseltamivir and zanamivir Sequencing was done using the Sanger method as described previously [12] . Primers used for RT-PCR and sequencing reactions are available upon request. In addition, the pyrosequencing assay was performed to detect H275Y mutation in the NA of pandemic H1N1 viruses as previously described [8] .
Results
Susceptibility to adamantanes
In total, 3,362 pandemic influenza A (H1N1) viruses from 73 countries, with 2,294 (68%) viruses from the US were tested for adamantane susceptibility by conventional sequencing and/or pyrosequencing analysis of the M2 gene, and 3,359 (99.9%) contained the S31N change in their M2 protein, which is the most commonly detected amino acid change conferring resistance to both amantadine and rimantadine. As of January 2010, only three pandemic viruses lacking the S31N change had been detected at the CDC. Of note, the M2 gene of all analysed viruses also encoded for the V28I amino acid change, characteristic for swine origin influenza viruses, as well as a unique substitution I43T not seen earlier in other swine or human influenza A viruses.
Because of continuous debates regarding the actual binding site of adamantanes and questions on the mechanism of resistance [13, 14] , it was prudent to assess the effect of adamantanes on viral replication in cell culture. A representative subset of pandemic viruses was tested in two phenotypic drug susceptibility assays. Seasonal influenza viruses, A/Washington/10/2008 (H1N1) and A/Florida/21/2008 (H1N1), with and without the S31N change, respectively, were used as controls. The viruses were first tested in the plaque inhibition assay (Figure 1) , where amantadine at concentrations from 0.39 to 6.25 µg/ml did not to inhibit the replication of the pandemic A/California/05/2009 virus. The threshold concentration of 1 µg/ml corresponds with the maximal concentrations achievable in blood and respiratory secretions during clinical use of amantadine at tolerable non-toxic doses [15] . Although plaque inhibition of seasonal and pandemic viruses with S31N mutation was observed at higher adamantane concentrations tested, and EC 50 values ranged from 11.50 to 57.20 µg/ ml (Table 1) , such high drug concentrations are unlikely to be clinically relevant because they do not represent concentrations achievable in treated humans.
To further confirm adamantane resistance, the viruses were tested in virus yield reduction assays. Amantadine and rimantadine at low concentrations of 0.39 µg/ml and 1.56 µg/ml, respectively, inhibited (by 1.6-4.0 log 10 ) replication of the pandemic A/Wisconsin/53/2009 and the seasonal virus A/ Florida/21/2008 viruses (both of which lack the S31N change), whereas there was no reduction of infectious yields of the pandemic and seasonal viruses carrying the S31N change in the M2 protein (Table 2) . Similar to the plaque inhibition assay results, virus yields of the pandemic and seasonal viruses with the S31N change were reduced at the higher concentrations tested; however, such reduction has previously been associated with non-specific action of the drug in cell culture [16] . Thus, biological laboratory tests show that the majority of 2009 pandemic H1N1 viruses are resistant to both amantadine and rimantadine, and validate the outcome of adamantane resistance assessment based on the presence of S31N change in their M2 protein using genetic methods (sequencing and pyrosequencing).
Susceptibility assessment to neuraminidase inhibitors
In this study, 3,359 pandemic virus isolates collected in the US (n=2,275) and 72 other countries (n=1,084) were tested for oseltamivir and zanamivir susceptibility in the chemiluminescent NI assay as described previously [9] . Box and whisker plot statistical analyses of the generated IC 50 values ( Figure 2 ) were performed to identify outliers. A total of 24 (0.7%) virus isolates were qualified as outliers for oseltamivir using the previously established criterion (IC 50 >X 0.75 +3IQR) and 23 of them were reported as oseltamivir-resistant viruses based on their increased IC 50 values and detection of H275Y mutation in their NA by pyrosequencing ( 50 values from the neuraminidase inhibition assays were not normally distributed, which necessitated log-transformation prior to analysis. The box contains 50% of the IC 50 values, representing the middle two quartiles (25-75%). The length of the box represents the interquartile range (IQR). The whiskers extend to the largest and smallest values in the central part of the distribution before the region containing outliers is reached. In this study, the statistical cutoff was set at 3×IQR from the 75th percentile (X 0.75 +3IQR). Outliers were defined as viruses with IC 50 >X 0.75 +3IQR. All viruses with IC 50 values above this cutoff (outliers) were excluded from the descriptive statistical analysis of IC 50 values for each respective drug. All viruses with neuraminidase mutations known to be associated with drug resistance, such as H275Y, that confer oseltamivir resistance were outliers. Outliers below the 25th percentile were not defined and were considered susceptible to the respective drug.
IC 50 value (6.24 nM) contained a mixture of H275 wild-type and H275Y variant viruses. The oseltamivirresistant viruses were collected from patients who had received this drug for prophylaxis or treatment of the pandemic virus infection.
An additional outlier, A/Maine/17/2009, with IC 50 values of 8.78 nM and 6.56 nM for oseltamivir and zanamivir, respectively, showed no known changes in the NA previously associated with resistance or reduced susceptibility to NAIs. When this virus isolate was further propagated and retested in the NI assay, its IC 50 values returned to normal levels despite showing an NA sequence that was identical to the prior passage. The increased NAI susceptibility of this latter passage might indicate that the isolate's previous passage contained a minor population of variants with reduced susceptibility, which was lost upon further propagation.
The remaining viruses were sensitive to oseltamivir and zanamivir with mean IC 50 values of 0.25 nM and 0.29 nM, respectively ( Table 3 ). The IC 50 for oseltamivir among sensitive viruses ranged from 0.05 nM to 2.41 nM, whereas those for zanamivir were between 0.04 nM and 1.24 nM. In addition, a subset of viruses (n=1,460) was tested for peramivir and all but the 23 oseltamivir-resistant H275Y mutants were sensitive to this drug with IC 50 values ranging from 0.03 nM to 0.50 nM. (Table 3) . A subset of viruses tested with the NAIs, laninamivir (n=134) and A-315675 (n=160), was fully susceptible to both NAIs with mean IC 50 values similar to those determined for oseltamivir and zanamivir (Table 3 ). All the oseltamivir-resistant H275Y variants retained full susceptibility to zanamivir, laninamivir and A-315675 in the NI assays (Table 3) .
In agreement with the susceptibility assessment in the NI assays, analysis of full NA sequences of a subset of the virus isolates (n=774) obtained by the conventional method revealed no changes at residues constituting the enzyme active site and/or residues previously associated with resistance or reduced susceptibility to NAIs.
Discussion
The vast majority of the 2009 pandemic influenza A (H1N1) viruses tested at the CDC were susceptible to drugs of a newer class, NAIs. Although the NA of pandemic H1N1 viruses is phylogenetically distant from that of the seasonal influenza A (H1N1) viruses [3] , their IC 50 values determined in the NI assays were similar to those of oseltamivir-and zanamivir-sensitive seasonal influenza A (H1N1) viruses [9] . During the 2007-2008 influenza season, the emergence and transmission of oseltamivir-resistant seasonal influenza A (H1N1) viruses with an H275Y (H274Y in N2 numbering) mutation in the NA was simultaneously observed in several countries globally [9, 17] . In the subsequent 2008-2009 influenza season, many countries reported up to 100% oseltamivir resistance in seasonal human A (H1N1) viruses. The rapid spread of oseltamivirresistant seasonal A (H1N1) viruses raised concerns that pandemic influenza A (H1N1) viruses might also develop resistance to NAIs, as a result of selective pressure or spontaneous mutation. Monitoring resistance to NAIs, therefore, needs to be enhanced as these agents are currently the only effective antivirals for treatment and chemoprophylaxis of pandemic influenza infections.
Two NI assays are most commonly used to assess the virus susceptibility to NAIs, the chemiluminescent [10] and the methylumbelliferone N-acetylneuraminic acid (MUNANA)-based fluorescent [18] assays. The resulting IC 50 values provide valuable information for detection of resistant viruses as well as for comparing potencies of different NAIs. However, the actual IC 50 values obtained in these two NI assays should not be used to draw a direct correlation with the drug concentrations needed to inhibit virus replication in the infected host.
Functional analysis of drug susceptibility (assay measuring inhibition of virus replication in cell culture for adamantanes or the NI assay for NAIs) is essential for surveillance and diagnosis of resistance because it allows detection of drug-resistant viruses with established as well as novel mutations in targeted proteins. This is especially relevant to the NA of the N1 subtype (for example, H1N1 and H5N1 viruses), for which NA crystal structure findings identified residues close to or within the 150-loop (for example, D151 and Q136) that are vulnerable to NAI resistance emergence [19, 20] . Current NI assays, however, require use of propagated viruses and can be challenging for surveillance laboratories when enhanced biosafety containment is required. Genetic analysis by conventional sequencing [21] or pyrosequencing [22] is useful because it allows detection of known markers of resistance directly in unpropagated clinical specimens. Cell-culture-based assays are desirable for initial screening of antiviral susceptibility in surveillance studies because of their ability to detect a broad range of resistance phenotypes. However, the interpretation of NAI susceptibility in cell-culture-based assays is unreliable and is complicated by several factors unique to NAIs [23] , such as the unpredictable influence of hemagglutinin's binding efficiency on the requirements for NA activity for virus spread to neighbouring cells. In contrast to NAIs, susceptibility to adamantanes can be assessed in cell-culture-based assays. The two cellculture-based assays utilized in this study strongly support the adamantane resistance of the pandemic viruses, which was first reported based on sequencing and pyrosequencing data [6] . Given the existing controversy regarding the location of functional binding site for adamantanes [13] , our findings are essential for confirmation of amantadine and rimantadine resistance in the majority of 2009 pandemic influenza A (H1N1) viruses, with the exception of the three viruses lacking the S31N change, most likely caused by natural genetic variation.
All 2009 pandemic influenza A (H1N1) viruses tested were resistant to both rimantadine and amantadine, as demonstrated by failure to inhibit virus replication in cell culture at drug concentrations achievable in treated individuals. Of note, extremely high concentrations of adamantane drugs can sometimes result in partial loss of inhibitory effect on otherwise drug-sensitive viruses, as was observed for the seasonal influenza virus A/ Florida/21/2008 (H1N1), which exhibited three plaques at the highest amantadine concentration, 100 µg/ml. A similar phenomenon was previously reported for this class of drugs [24] .
Resistance to adamantanes is widespread among human influenza A viruses of H3N2 subtypes, as well as in some seasonal H1N1 viruses circulating in certain geographic areas [25, 26] . The resistance has also been reported in swine H1N1 and H3N2 viruses in Eurasia [27, 28] , and among some avian H5N1 viruses in Southeast Asia [29, 30] . Rapid emergence of resistance to adamantanes, first observed several years ago, has greatly compromised the effectiveness of this class of drugs [31] . A number of new adamantane derivatives [32] and structurally more distantly related compounds [33] have shown in vitro activity against influenza A, and might be useful against resistant variants, but have yet to be studied in animal models and in humans.
Because of the recent trends in influenza antiviral resistance, the current arsenal of licensed anti-influenza drugs is very limited. Options for combination therapy of the currently licensed influenza antivirals remain limited as well [34] . Moreover, these drugs are not licensed for use in combination with one another. Although the situation might improve as new antivirals are developed [34] , the development of new potent and safe antiviral drugs is a long and expensive process.
In addition to FDA-approved NAIs, peramivir, a cyclopentane derivative, was also used in this study, and exhibited the highest inhibitory effect on tested pandemic viruses. Currently, peramivir is being developed as an intravenous formulation, as it has demonstrated poor protection against seasonal influenza H1N1 infection when used orally in humans [35] . When administered intramuscularly or intravenously in mice, the compound is highly protective against influenza H1N1 [36] and H5N1 viruses [37, 38] . During the pandemic, peramivir became available in the US under an emergency use authorization [39] and is now licensed in Japan [40] .
Of note, in this study, the H275Y mutation increased the IC 50 values for peramivir and thus might reduce its antiviral effect in vivo. Lack of a virological response to intravenous peramivir was recently reported in two immunocompromised patients infected with oseltamivirresistant 2009 pandemic influenza A (H1N1) [41] , suggesting a potential clinical relevance of reduced peramivir susceptibility in H275Y mutants detected in the NI assays (the IC 50 was approximately 10 nM); however, more clinical studies are required to address this question. There is some similarity in the interaction of hydrophobic groups of oseltamivir and peramivir with the NA active site [42] . The H275Y mutation creates a steric barrier to the reorientation of E276 in the NA active site [43] , thus, preventing effective binding of oseltamivir and peramivir. Laninamivir is the simple 7-O-methyl ether of zanamivir [44] that is being developed by Daiichi Sankyo and Biota as an inhaled prodrug (CS-8958). It is therefore not surprising that the H275Y mutants in this study retained susceptibility to laninamivir. Studies have shown that laninamivir has long-acting anti-influenza virus activity in vivo [44] [45] [46] [47] and is currently undergoing late-stage clinical trials in Japan as a once-only dose for treatment [48] . The NAI A-315675 (Abbott Laboratories), a pyrrolidine derivative, despite showing significant inhibitory effects [49, 50] , was dropped from development for commercial reasons. A-315675 has a drug resistance profile that differs from those of zanamivir, oseltamivir and peramivir [51] and, as shown in the present study, H275Y mutants of the 2009 pandemic viruses retained full susceptibility to this NAI.
Emergence of oseltamivir-resistant H275Y mutants among 2009 pandemic A (H1N1) viruses, as well as the potential for emergence of Q136 [52, 53] and other mutants [19] in the NA responsible for reduced susceptibly to zanamivir, emphasize an urgent need for the development of novel antivirals that can effectively prevent and treat influenza infections. Current priorities for new antiviral drug design include developing appropriate formulations, studying mechanisms and clinical significance of drug resistance, and identifying new antiviral therapies that target different stages of the viral life cycle and thus limiting the effect of emerging drug resistance.
The results of this study establish a baseline for referral in the event that the 2009 pandemic influenza A (H1N1) viruses acquire mutations that would make them less susceptible to NAIs or more sensitive to adamantanes. The widespread resistance to adamantanes among these viruses makes this class of inexpensive drugs obsolete. To date, the 2009 pandemic influenza A (H1N1) viruses circulating in communities are susceptible to the licensed NAIs, oseltamivir, with rare exception (<1%), and zanamivir [54] . The appropriate use of the available NAIs will aid strategies to reduce morbidity and mortality caused by influenza viruses; however, with the potential emergence and spread of oseltamivir-resistant H275Y variants, new experimental therapies could become increasingly important.
